Clinical

July 30, 2021

After controlling for variables, eldery-onset rheumatoid arthritis (EORA) was not indicative of changes in Clinical Disease Activity Index (CDAI) scores over time when compared with a non-EORA cohort. Further, there were no significant differences in the efficacy and safety of receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).

December 17, 2020

In this episode of Overdrive, the Rheumatology Network podcast, Dr. Kim Gorgens interviews Shereen Mahmood, MD, a rheumatologist with the Montefiore Medical Center in South Bronx, New York, to discuss her experience as a physician during the COVID-19 pandemic.

December 14, 2020

Patients who had received tofacitinib combination therapy may be able to discontinue methotrexate.